Commonwealth Equity Services’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$21.5M Sell
109,247
-5,116
-4% -$986K 0.03% 539
2025
Q4
$21M Buy
114,363
+18,426
+19% +$3.23M 0.03% 539
2025
Q3
$14.7M Sell
95,937
-4,337
-4% -$656K 0.02% 710
2025
Q2
$14M Sell
100,274
-3,648
-4% -$511K 0.02% 724
2025
Q1
$15.3M Buy
103,922
+7,705
+8% +$1.11M 0.02% 667
2024
Q4
$12.6M Sell
96,217
-445
-0.5% -$62.3K 0.02% 710
2024
Q3
$15.1M Sell
96,662
-7,871
-8% -$1.27M 0.02% 635
2024
Q2
$16.3M Buy
104,533
+2,846
+3% +$428K 0.03% 589
2024
Q1
$13.8M Buy
101,687
+9,901
+11% +$1.31M 0.02% 646
2023
Q4
$12.4M Buy
91,786
+1,874
+2% +$244K 0.02% 640
2023
Q3
$12.2M Buy
89,912
+105
+0.1% +$14.3K 0.03% 595
2023
Q2
$12.9M Buy
89,807
+4,556
+5% +$670K 0.03% 585
2023
Q1
$11.8K Buy
85,251
+1,262
+2% +$170K 0.02% 594
2022
Q4
$11.4M Buy
83,989
+2,995
+4% +$376K 0.03% 578
2022
Q3
$8.88M Sell
80,994
-2,167
-3% -$275K 0.02% 625
2022
Q2
$11M Buy
83,161
+222
+0.3% +$29.1K 0.03% 544
2022
Q1
$11M Buy
82,939
+2,741
+3% +$329K 0.03% 586
2021
Q4
$9.34M Sell
80,198
-615
-0.8% -$72.4K 0.02% 627
2021
Q3
$9.71M Buy
80,813
+9,391
+13% +$1.09M 0.02% 584
2021
Q2
$8.56M Sell
71,422
-7,012
-9% -$769K 0.02% 616
2021
Q1
$7.8M Sell
78,434
-13,740
-15% -$1.38M 0.02% 592
2020
Q4
$9.21M Sell
92,174
-897
-1% -$95K 0.03% 499
2020
Q3
$10.2M Buy
93,071
+18,945
+26% +$2.11M 0.03% 425
2020
Q2
$7.84M Buy
74,126
+4,661
+7% +$481K 0.03% 481
2020
Q1
$6.2M Sell
69,465
-1,995
-3% -$188K 0.03% 480
2019
Q4
$7.13M Buy
71,460
+637
+0.9% +$60K 0.03% 513
2019
Q3
$6.31M Buy
70,823
+2,210
+3% +$192K 0.03% 519
2019
Q2
$5.66M Buy
68,613
+5,467
+9% +$429K 0.03% 525
2019
Q1
$5.11M Buy
63,146
+1,005
+2% +$79.2K 0.02% 551
2018
Q4
$4.72M Buy
62,141
+193
+0.3% +$15.1K 0.03% 514
2018
Q3
$4.9M Buy
61,948
+1,730
+3% +$131K 0.02% 536
2018
Q2
$4.23M Sell
60,218
-2,214
-4% -$159K 0.02% 568
2018
Q1
$4.37M Buy
62,432
+2,058
+3% +$143K 0.02% 526
2017
Q4
$4.19M Sell
60,374
-477
-0.8% -$32.2K 0.02% 533
2017
Q3
$4.12M Buy
60,851
+2,770
+5% +$175K 0.02% 514
2017
Q2
$3.96M Sell
58,081
-5,209
-8% -$340K 0.03% 511
2017
Q1
$3.94M Buy
63,290
+3,416
+6% +$199K 0.03% 499
2016
Q4
$3.27M Buy
59,874
+16,058
+37% +$912K 0.02% 523
2016
Q3
$2.88M Buy
43,816
+1,021
+2% +$66.7K 0.02% 534
2016
Q2
$2.58M Sell
42,795
-1,332
-3% -$77.4K 0.02% 550
2016
Q1
$2.48M Buy
44,127
+2,693
+6% +$162K 0.02% 549
2015
Q4
$2.81M Buy
41,434
+1,833
+5% +$120K 0.03% 510
2015
Q3
$2.52M Buy
39,601
+1,124
+3% +$73.9K 0.03% 509
2015
Q2
$2.45M Sell
38,477
-298
-0.8% -$20.4K 0.02% 553
2015
Q1
$2.65M Buy
38,775
+659
+2% +$45.8K 0.03% 514
2014
Q4
$2.68M Sell
38,116
-1,773
-4% -$127K 0.03% 470
2014
Q3
$2.85M Buy
39,889
+1,553
+4% +$114K 0.03% 433
2014
Q2
$2.85M Sell
38,336
-9,129
-19% -$660K 0.03% 433
2014
Q1
$3.08M Buy
47,465
+3,880
+9% +$251K 0.04% 365
2013
Q4
$2.59M Buy
43,585
+2,078
+5% +$113K 0.04% 400
2013
Q3
$2.15M Buy
41,507
+5,513
+15% +$277K 0.04% 430
2013
Q2
$1.7M Buy
+35,994
New +$1.83M 0.03% 472

Other funds holding AZN

Commonwealth Equity Services's AZN Position: Q1 2026 in Review

Commonwealth Equity Services reduced its AstraZeneca (AZN) stake by 4.5% in Q1 2026, selling an estimated $986K and leaving 109,247 shares worth $21.5M. The position accounts for 0.03% of the portfolio, ranked #539.

Commonwealth Equity Services first reported a position in AZN in Q2 2013 and has held it in 52 quarters since. 1,378 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Commonwealth Equity Services held 109,247 shares of AstraZeneca worth $21.5M as of Q1 2026.
  • Commonwealth Equity Services sold 5,116 AstraZeneca shares in Q1 2026, an estimated $986K.
  • AstraZeneca made up 0.03% of Commonwealth Equity Services's portfolio in Q1 2026, its #539 holding.
  • Commonwealth Equity Services first reported a position in AstraZeneca in Q2 2013 and has held it in 52 quarters since.
  • 1,378 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.